Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing, Sheng Yang, Dan Wang, Guibing Wang, Shasha Wang, Jiarui Yao, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiaohong Han, Yuankai Shi
The response rate of anti-PD1 therapy is limited, and the influence of anti-PD1 therapy on cancer patients is unclear. To address these challenges, we conducted a longitudinal analysis of plasma proteomic changes with anti-PD1 therapy in non-small cell lung cancer (NSCLC), alveolar soft part sarcoma (ASPS), and lymphoma patients. We included 339 plasma samples before and after anti-PD1 therapy from 193 patients with NSCLC, ASPS, or lymphoma. The plasma proteins were detected using data-independent acquisition-mass spectrometry and customable antibody microarrays...
February 13, 2024: Cancer Immunology, Immunotherapy: CII